Associate Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine

Endocrinology

Cyrus Desouza practices Endocrinology. He studied medicine at St. John's Medical College. He over the years received 1 awards: "Fellow (FACE)". Cyrus Desouza is a published doctor. He published 37 publications, including: 'Protocol for the Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER) Trial: Comparing three obesity treatment models in rural primary care.' He is registered with Medicare.

Publications

---

• Protocol for the Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER) Trial: Comparing three Obesity treatment models in rural primary care.
• GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS.
• Effect of paricalcitol on endothelial function and inflammation in type 2 Diabetes and chronic kidney disease.
• Cardiometabolic Effects of a New Class of Antidiabetic Agents.
• Differential effects of eicosapentaenoic acid and docosahexaenoic acid in promoting the differentiation of 3T3-L1 preadipocytes.
• Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes (TINSAL): Effects on flow-mediated dilation.
• Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic Disorders in mice.
• Does drug therapy reverse endothelial progenitor cell dysfunction in Diabetes?
• Metanx in type 2 Diabetes with peripheral neuropathy: a randomized trial.
• Diabetes and Cardiovascular Disease Following Kidney Transplantation.
• Role of inflammation and insulin resistance in endothelial progenitor cell Dysfunction.
• Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats.
• Hypoglycemia, Diabetes, and cardiovascular events.
• Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
• Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats.
• Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zuc...
• Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and Diabetes.
• Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats.
• The effect of group clinics in the control of Diabetes.
• The impact of apathy on glycemic control in Diabetes: a cross-sectional study.
• Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 Diabetes and the effects of pharmacologic intervention.
• The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine Metabolism...
• Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.
• Gain of function of cardiac ryanodine receptor in a rat model of type 1 Diabetes.
• Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 Diabetes.
• Therapeutic targets to reduce cardiovascular disease in type 2 Diabetes.
• Effects of the thiazolidinediones on cardiovascular risk factors.
• Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet.
• An overview of salsalate as a potential antidiabetic therapy.
• Drugs affecting homocysteine Metabolism: impact on cardiovascular risk.
• Hormones and homocysteine.
• Nontraditional risk factors for cardiovascular disease in Diabetes.
• Management of the insulin resistance Syndrome.
• Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 Diabetes is poorly controlled with metformin alone.
• The enigma of glucose and cardiovascular disease.
• Does pioglitazone reduce carotid intima-media thickness in patients with type 2 Diabetes mellitus?

Conditions Treated

---

• Abnormal Thyroid
• Adrenal Insufficiency
• Calcium Metabolism Disorders
• Diabetes Type 2
• View All

Doctors Specialties

---

• Endocrinology

Accepted Insurances

---

Awards

---

• Fellow (FACE)

Education

---

• Tulane University
• St Barnabas Hospital
• St. John's Medical College

Drug Facts

---

NPI NUMBER		1346298148
NPPES Provider LastName		DESOUZA
NPPES Provider FirstName		CYRUS
NPPES Provider ZIPCode		681988095
NPPES Provider State		NE
Specialty Description		Endocrinology
Total Claim Count		11.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1346298148
Last Name Of The Provider	DESOUZA
First Name Of The Provider	CYRUS
View All

Similar Doctors

---

	Ritu Madan, MB BS
	Dr. Timothy O. Wahl, MD This Doctor is OpenDoctor Recommended.
	Dr. J C. Gallagher, MD This Doctor is OpenDoctor Recommended.
	Dr. Sarah B. Konigsberg, MD This Doctor is OpenDoctor Recommended.
	Dr. Brian P. Boerner, MD This Doctor is OpenDoctor Recommended.
	Dr. Marc S. Rendell, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Amy S. Neumeister, MD This Doctor is OpenDoctor Recommended.
	Dr. Andjela T. Drincic, MD This Doctor is OpenDoctor Recommended.
	Dr. Claire H. Baker, MD This Doctor is OpenDoctor Recommended.
	Dr. Jennifer L. Larsen, MD This Doctor is OpenDoctor Recommended.
	Dr. Paul Steffes, MD This Doctor is OpenDoctor Recommended.
	Dr. Alain Taylon, MD This Doctor is OpenDoctor Recommended.
	Dr. Alejandro G. Trepp Carrasco, MD This Doctor is OpenDoctor Recommended.
	Dr. Leslie A. Eiland, MD This Doctor is OpenDoctor Recommended.
	Dr. Lynn R. Mack, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog